Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 2Genitourinary 1Gastrointestinal 1

Conditions

Esophageal Neoplasms 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 140Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Trastuzumab 32Ramucirumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × sotigalimab × Gastrointestinal × Clear all
NCT03165994 2024-05-02

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Apexigen America, Inc.

Phase 2 Completed
34 enrolled 18 charts
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡